Lynparza is an oral medication used to treat certain types of cancer, including ovarian, breast, prostate, and pancreatic cancers [1]. It is a PARP inhibitor, meaning it works by blocking the activity of poly(ADP-ribose) polymerase (PARP) enzymes, which play a role in DNA repair [1].
What is the mechanism of action for Lynparza?
Lynparza targets and inhibits PARP enzymes. These enzymes are involved in repairing single-strand DNA breaks. In cancer cells that have specific genetic mutations, such as those in BRCA genes, the ability to repair DNA is already compromised. By inhibiting PARP, Lynparza prevents the repair of DNA breaks, leading to the accumulation of DNA damage and ultimately cell death in these cancer cells [1]. This mechanism is particularly effective in cancers with homologous recombination deficiency (HRD).
When does Lynparza patent exclusivity expire?
The patent landscape for Lynparza is complex and involves multiple patents covering its composition of matter, methods of use, and manufacturing processes. While specific expiry dates can vary by patent and region, and can be extended due to factors like pediatric exclusivity or patent challenges, information from sources like DrugPatentWatch.com suggests that key patents have expiration dates that extend into the late 2020s and beyond for certain applications [2]. Understanding these dates is crucial for potential generic or biosimilar manufacturers.
Who manufactures Lynparza?
Lynparza is developed and marketed by AstraZeneca and Merck & Co., Inc. (known as MSD outside the United States and Canada) [1].
What are the approved uses for Lynparza?
Lynparza has received approval for several indications:
* Ovarian Cancer: It is used for the maintenance treatment of adult patients with advanced ovarian cancer, fallopian tube, or primary peritoneal cancer who are in response to first- or second-line platinum-based chemotherapy [1]. It is also approved for patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (as determined by an FDA-approved test) advanced ovarian cancer, who have been treated with three or more prior lines of chemotherapy [1].
* Breast Cancer: Lynparza is indicated for patients with deleterious or suspected deleterious germline BRCA-mutated (tested using a diagnostic test) metastatic breast cancer, who have previously been treated with an anthracycline or a taxane, and have had prior therapy with a chemotherapy agent for metastatic disease or recurrence of disease whilst on or within 6 months of finishing adjuvant chemotherapy [1].
* Prostate Cancer: It is used for adult patients with BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with docetaxel [1].
* Pancreatic Cancer: Lynparza is approved for adult patients with deleterious or suspected deleterious germline BRCA-mutated (tested using a diagnostic test) metastatic pancreatic cancer (mPDAC), who have been treated with at least one prior line of systemic therapy [1].
What are the potential side effects of Lynparza?
Common side effects associated with Lynparza treatment include anemia, nausea, fatigue, headache, decreased appetite, vomiting, diarrhea, neutropenia, and thrombocytopenia [1]. More serious side effects can include myelodysplastic syndrome/acute myeloid leukemia (MDS/AML), and pneumonitis [1]. Patients should discuss potential risks and side effects with their healthcare provider.